With its pilot facility now fully operational, Thor Medical has secured a string of strategic supply agreements that propel the company toward full-scale commercial production. This commercial momentum has led to to the investment in AlphaOne, the company's first industrial-scale facility, positioning Thor Medical as a key supplier of alpha-emitters for next-generation precision cancer treatments. BioStock contacted CEO Jasper Kurth to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/thor-medical-tar-klivet-mot-kommersiell-produktion-efter-framgangsrik-pilot-och-intensiv-avtalsperiod/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se